Azitra Records $11M 2025 Net Loss, Doses First Patient in ATR-04 Trial
Azitra posted a $11.0M net loss for 2025 on $4.8M R&D and $6.2M G&A expenses, and ended the year with $2.1M in cash. The company dosed its first patient in the ATR-04 Phase 1/2 trial, reported positive ATR-01 preclinical data, and expects multiple topline readouts in 2026.
1. Financial Results
Azitra reported a net loss of $11.0 million for the year ended December 31, 2025, compared to a $9.0 million loss in 2024. R&D expenses were $4.8 million, G&A expenses $6.2 million, and cash and cash equivalents stood at $2.1 million as of year-end.
2. Pipeline Progress
In Q3 2025 Azitra dosed the first patient in its ATR-04 Phase 1/2 trial for EGFR inhibitor–associated rash, a program granted Fast Track designation. The company also reported positive ATR-01 preclinical results demonstrating functional filaggrin delivery for ichthyosis vulgaris and observed promising safety in its ATR-12 Phase 1b Netherton syndrome trial.
3. Upcoming Milestones
Azitra expects topline data from the ATR-12 Phase 1b trial in Netherton syndrome in H2 2026 and from the ATR-04 Phase 1/2 first cohort around mid-2026. IND-enabling studies for ATR-01 are slated to complete in 2026 as the company advances its pipeline.